Signatera ctDNA in stage II CRC: A retrospective comparison with traditional risk factors for survival and prognostic stratification.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e15641
Abstract: e15641 Background: Stage II colorectal cancer (CRC) presents a clinical challenge due to variable recurrence risk and uncertain benefits of adjuvant chemotherapy. This study evaluates the prognostic value of Signatera circulating tumor DNA (ctDNA) analysis(a… read more here.
Keywords: signatera; risk; high risk; stage crc ... See more keywords